Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Treasury Shares (2016 - 2025)

Tg Therapeutics has reported Treasury Shares over the past 10 years, most recently at $100.2 million for Q4 2025.

  • Quarterly results put Treasury Shares at $100.2 million for Q4 2025, up 1014.08% from a year ago — trailing twelve months through Dec 2025 was $100.2 million (up 1014.08% YoY), and the annual figure for FY2025 was $100.2 million, up 1014.08%.
  • Treasury Shares for Q4 2025 was $8.8 million at Tg Therapeutics, up from $3.8 million in the prior quarter.
  • Over the last five years, Treasury Shares for TGTX hit a ceiling of $12.1 million in Q3 2024 and a floor of $41309.0 in Q1 2021.
  • Median Treasury Shares over the past 5 years was $664348.0 (2025), compared with a mean of $4.5 million.
  • Biggest five-year swings in Treasury Shares: changed 0.0% in 2021 and later skyrocketed 9298.29% in 2025.
  • Tg Therapeutics' Treasury Shares stood at $234000.0 in 2021, then changed by 0.0% to $234000.0 in 2022, then changed by 0.0% to $234000.0 in 2023, then soared by 3743.59% to $9.0 million in 2024, then skyrocketed by 1014.08% to $100.2 million in 2025.
  • The last three reported values for Treasury Shares were $100.2 million (Q4 2025), $100.2 million (Q3 2025), and $22.0 million (Q2 2025) per Business Quant data.